Parsec Financial Management’s Bristol-Myers Squibb BMY Stock Holding History

Parsec Financial Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$13M	Sell	187,426 -22,517	-11%	-$1.59M	0.55%	49
2022 Q4	$15.1M	Buy	209,943 +4,092	+2%	+$309K	0.67%	42
2022 Q3	$14.6M	Buy	205,851 +28,322	+16%	+$2.05M	0.73%	38
2022 Q2	$13.7M	Buy	177,529 +13,589	+8%	+$1.03M	0.66%	42
2022 Q1	$12M	Buy	163,940 +42,446	+35%	+$2.85M	0.51%	51
2021 Q4	$7.58M	Buy	121,494 +6,397	+6%	+$375K	0.31%	64
2021 Q3	$6.84M	Buy	115,097 +42,276	+58%	+$2.78M	0.29%	68
2021 Q2	$4.87M	Buy	72,821 +24,989	+52%	+$1.63M	0.23%	74
2021 Q1	$3.02M	Buy	47,832 +40,444	+547%	+$2.52M	0.16%	101
2020 Q4	$458K	Buy	7,388 +2,468	+50%	+$152K	0.02%	182
2020 Q3	$297K	Buy	4,920 +911	+23%	+$54.8K	0.02%	206
2020 Q2	$236K	Sell	4,009 -20	-0.5%	-$1.2K	0.02%	214
2020 Q1	$225K	Buy	4,029 +633	+19%	+$38.7K	0.02%	211
2019 Q4	$218K	Sell	3,396 -600	-15%	-$34.4K	0.01%	235
2019 Q3	$203K	Buy	+3,996	New	+$188K	0.01%	232
2019 Q2	–	Sell	-4,197	Closed	-$200K	–	240
2019 Q1	$200K	Sell	4,197 -4,721	-53%	-$235K	0.01%	224
2018 Q4	$464K	Sell	8,918 -66	-0.7%	-$3.55K	0.03%	171
2018 Q3	$558K	Buy	8,984 +441	+5%	+$26.2K	0.04%	169
2018 Q2	$473K	Buy	8,543 +1,168	+16%	+$63.1K	0.03%	177
2018 Q1	$466K	Hold	7,375	–	–	0.03%	182
2017 Q4	$452K	Buy	7,375 +326	+5%	+$20.4K	0.03%	188
2017 Q3	$449K	Sell	7,049 -251	-3%	-$14.7K	0.03%	188
2017 Q2	$407K	Sell	7,300 -147	-2%	-$8K	0.03%	159
2017 Q1	$405K	Buy	7,447 +475	+7%	+$26.1K	0.03%	150
2016 Q4	$407K	Sell	6,972 -800	-10%	-$43.7K	0.04%	151
2016 Q3	$419K	Buy	7,772 +945	+14%	+$60.7K	0.04%	150
2016 Q2	$502K	Sell	6,827 -800	-10%	-$56.5K	0.05%	138
2016 Q1	$487K	Buy	7,627 +503	+7%	+$31.7K	0.05%	136
2015 Q4	$490K	Buy	7,124 +1,025	+17%	+$67.7K	0.05%	134
2015 Q3	$361K	Hold	6,099	–	–	0.04%	139
2015 Q2	$406K	Buy	6,099 +197	+3%	+$13K	0.04%	141
2015 Q1	$381K	Sell	5,902 -175	-3%	-$11K	0.04%	142
2014 Q4	$359K	Buy	6,077 +300	+5%	+$16.9K	0.04%	131
2014 Q3	$296K	Buy	5,777 +186	+3%	+$9.29K	0.03%	136
2014 Q2	$271K	Hold	5,591	–	–	0.03%	140
2014 Q1	$290K	Hold	5,591	–	–	0.03%	133
2013 Q4	$297K	Sell	5,591 -363	-6%	-$18.5K	0.03%	121
2013 Q3	$276K	Buy	5,954 +593	+11%	+$26K	0.04%	115
2013 Q2	$240K	Buy	+5,361	New	+$233K	0.03%	120

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Parsec Financial Management's BMY Position: Q1 2023 in Review

Parsec Financial Management reduced its Bristol-Myers Squibb (BMY) stake by 11% in Q1 2023, selling an estimated $1.59M and leaving 187,426 shares worth $13M. The position accounts for 0.55% of the portfolio, ranked #49.

Parsec Financial Management first reported a position in BMY in Q2 2013 and has held it in 39 quarters since. The position peaked at $15.1M in Q4 2022. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

Parsec Financial Management held 187,426 shares of Bristol-Myers Squibb worth $13M as of Q1 2023.
Parsec Financial Management sold 22,517 Bristol-Myers Squibb shares in Q1 2023, an estimated $1.59M.
Bristol-Myers Squibb made up 0.55% of Parsec Financial Management's portfolio in Q1 2023, its #49 holding.
Parsec Financial Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 39 quarters since.
Parsec Financial Management's Bristol-Myers Squibb position peaked at $15.1M in Q4 2022.
2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Parsec Financial Management's 13F filing for Q1 2023, filed 6 Apr 2023.